Sheng XN - Search Results

1

Role of Carotid Ultrasonography Combined with Monocyte/HDL Ratio in Internal Carotid Artery Stenosis.

Bao MQ, Chen YN, Jin JW, Gui DD, Wang J, Chen SS, Sheng XN, Cheng ZL, Wang Y. Bao MQ, et al. Among authors: sheng xn. Curr Med Imaging. 2024 Apr 18. doi: 10.2174/0115734056289735240409083434. Online ahead of print. Curr Med Imaging. 2024. PMID: 38639287

2

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Yan XQ, et al. Among authors: sheng xn. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37872020 Free article. Clinical Trial.

3

Multi-networks connectivity at baseline predicts the clinical efficacy of left angular gyrus-navigated rTMS in the spectrum of Alzheimer's disease: A sham-controlled study.

Chen HF, Sheng XN, Yang ZY, Shao PF, Xu HH, Qin RM, Zhao H, Bai F. Chen HF, et al. Among authors: sheng xn. CNS Neurosci Ther. 2023 Aug;29(8):2267-2280. doi: 10.1111/cns.14177. Epub 2023 Mar 21. CNS Neurosci Ther. 2023. PMID: 36942495 Free PMC article. Clinical Trial.

4

Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.

Lian B, Si L, Chi ZH, Sheng XN, Kong Y, Wang X, Tian H, Li K, Mao LL, Bai X, Tang BX, Yan XQ, Li SM, Zhou L, Dai J, Tang XW, Ran FW, Yao S, Guo J, Cui CL. Lian B, et al. Among authors: sheng xn. Ann Oncol. 2022 Oct;33(10):1061-1070. doi: 10.1016/j.annonc.2022.07.002. Epub 2022 Jul 14. Ann Oncol. 2022. PMID: 35842199 Free article. Clinical Trial.

5

[Preliminary effects of toripalimab combined with axitinib in the treatment of advanced renal cell carcinoma].

Zhou L, Xu HY, Yan XQ, Li SM, Chi ZH, Si L, Cui ZL, Li J, Wu XW, Guo J, Sheng XN. Zhou L, et al. Among authors: sheng xn. Zhonghua Yi Xue Za Zhi. 2022 Jan 11;102(2):136-140. doi: 10.3760/cma.j.cn112137-20210527-01225. Zhonghua Yi Xue Za Zhi. 2022. PMID: 35012303 Chinese.

6

[Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma].

Li X, Sheng XN, Chi ZH, Cui CL, Si L, Mao LL, Tang BX, Lian B, Wang X, Yan XQ, Li SM, Bai X, Zhou L, Kong Y, Dai J, Guo J. Li X, et al. Among authors: sheng xn. Zhonghua Yi Xue Za Zhi. 2018 Aug 28;98(32):2574-2578. doi: 10.3760/cma.j.issn.0376-2491.2018.32.008. Zhonghua Yi Xue Za Zhi. 2018. PMID: 30220142 Chinese.

7

BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.

Bai X, Mao LL, Chi ZH, Sheng XN, Cui CL, Kong Y, Dai J, Wang X, Li SM, Tang BX, Lian B, Zhou L, Yan XQ, Guo J, Si L. Bai X, et al. Among authors: sheng xn. Neoplasma. 2017;64(4):626-632. doi: 10.4149/neo_2017_419. Neoplasma. 2017. PMID: 28485171

8

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.

Zhang HL, Sheng XN, Li XS, Wang HK, Chi ZH, He ZS, Ye DW, Guo J. Zhang HL, et al. Among authors: sheng xn. BMC Cancer. 2017 Jan 5;17(1):16. doi: 10.1186/s12885-016-3016-4. BMC Cancer. 2017. PMID: 28056874 Free PMC article.

9

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients.

Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, Si L, Chi ZH, Sheng XN, Mao LL, Wang X, Tang BX, Yan XQ, Kong Y, Dai J, Li SM, Bai X, Zheng N, Balch CM, Guo J. Lian B, et al. Among authors: sheng xn. Ann Oncol. 2017 Apr 1;28(4):868-873. doi: 10.1093/annonc/mdw694. Ann Oncol. 2017. PMID: 28039178 Free article.

10

[Efficacy and the multivariate analysis of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma].

Chen XL, Sheng XN, Chi ZH, Cui CL, Si L, Mao LL, Tang BX, Wang X, Lian B, Yan XQ, Kong Y, Guo J. Chen XL, et al. Among authors: sheng xn. Zhonghua Yi Xue Za Zhi. 2016 Oct 18;96(38):3053-3056. doi: 10.3760/cma.j.issn.0376-2491.2016.38.004. Zhonghua Yi Xue Za Zhi. 2016. PMID: 27784444 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page